Fig. 5.

Modulation of the cytotoxic activity of Vγ9Vδ2 T cells by blocking the NKG2D and TCR interactions. PBMCs from two donors were treated at day 0 with 300 nM BrHPP and cultured in presence of 400 IU IL-2/ml within 2 weeks. Expanded Vγ9Vδ2 T cells were incubated with mAb anti-NKG2D or/and anti-pan-γδ-TCR and then co-cultured for 4 h with 5 × 10³ cells from cell lines previously labeled with ⁵¹Cr at an effector to target (E/T) ratio of 50/1. Data are mean ± SD of experiments with C181 (n = 6) and HuH7 (n = 6) target cell lines. *, P ≤ 0.03 compared with isotype control